NASDAQ:ALNY Alnylam Pharmaceuticals (ALNY) Insider Trading & Ownership $174.86 +4.09 (+2.40%) (As of 02:52 PM ET) Add Compare Share Share Today's Range$170.05▼$175.0050-Day Range$170.77▼$211.6552-Week Range$168.65▼$242.97Volume378,148 shsAverage Volume682,589 shsMarket Capitalization$21.86 billionP/E RatioN/ADividend YieldN/APrice Target$247.40 Insider TradesProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Alnylam Pharmaceuticals (NASDAQ:ALNY) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage1.40%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)6Amount OfInsider Selling(Last 12 Months)$10.32 M Get ALNY Insider Trade Alerts Want to know when executives and insiders are buying or selling Alnylam Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address ALNY Insider Buying and Selling by Quarter Alnylam Pharmaceuticals Insider and Congressional Trades History Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails8/7/2023Pushkal GargCMOSell4,166$183.89$766,085.744,345 8/4/2023Jeffrey V PoultonCFOSell3,460$185.85$643,041.0015,873 8/4/2023Pushkal GargCMOSell3,461$185.85$643,226.858,511 8/4/2023Yvonne GreenstreetCEOSell4,057$185.85$753,993.4535,216 4/27/2023Akshay VaishnawPresidentSell2,392$194.59$465,459.2817,890 4/27/2023Jeffrey V PoultonCFOSell977$194.59$190,114.4311,706 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 4/27/2023Pushkal GargCMOSell1,839$194.59$357,851.016,800 4/27/2023Tolga TangulerEVPSell1,476$194.59$287,214.841,801 4/27/2023Yvonne GreenstreetCEOSell7,615$194.59$1,481,802.8530,332 4/6/2023Indrani Lall FranchiniEVPSell3,500$210.00$735,000.00 3/6/2023Daniel S. GoldmanU.S. Congress Member (D-NY)Buy$199.70$15,001 - $50,0003/3/2023Pushkal GargCMOSell18,072$200.00$3,614,400.004,345 2/2/2023Indrani Lall FranchiniEVPSell1,675$226.01$378,566.753,500 (Data available from 1/1/2013 forward) ALNY Insider Trading Activity - Frequently Asked Questions Who is on Alnylam Pharmaceuticals's Insider Roster? The list of insiders at Alnylam Pharmaceuticals includes Akshay Vaishnaw, Indrani Lall Franchini, Jeffrey V Poulton, John Maraganore, Laurie Keating, Phillip A Sharp, Pushkal Garg, Steven M Paul, Tolga Tanguler, and Yvonne Greenstreet. Learn more on insiders at ALNY. What percentage of Alnylam Pharmaceuticals stock is owned by insiders? 1.40% of Alnylam Pharmaceuticals stock is owned by insiders. Learn more on ALNY's insider holdings. Which Alnylam Pharmaceuticals insiders have been selling company stock? The following insiders have sold ALNY shares in the last 24 months: Akshay Vaishnaw ($1,015,146.75), Indrani Lall Franchini ($1,113,566.75), Jeffrey V Poulton ($833,155.43), John Maraganore ($5,827,906.56), Pushkal Garg ($5,381,563.60), Steven M Paul ($2,560,350.00), Tolga Tanguler ($1,320,287.40), and Yvonne Greenstreet ($2,235,796.30). How much insider selling is happening at Alnylam Pharmaceuticals? Insiders have sold a total of 109,896 Alnylam Pharmaceuticals shares in the last 24 months for a total of $20,287,772.79 sold. More Insider Trading Tools from MarketBeat Related Companies: United Therapeutics Insider Trades Ionis Pharmaceuticals Insider Trades BeiGene Insider Trades Horizon Therapeutics Public Insider Trades Viatris Insider Trades Teva Pharmaceutical Industries Insider Trades Verona Pharma Insider Trades Sarepta Therapeutics Insider Trades Catalent Insider Trades Roivant Sciences Insider Trades Insider Tracking Tools: CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Insider Trading By Country: U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles: Insiders and Institutions are Scooping Up SelectQuoteInstitutions and Insiders Are Gobbling Up Shares of HASIInsiders Are Buying These 2 Stocks3 Health Companies with Healthy Insider Buying and Market Support2 Cheap Stocks The Insiders Are Buying This page (NASDAQ:ALNY) was last updated on 9/26/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alnylam Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.